The Efficacy and Safety of Low-frequency Rotating Static Magnetic Field Therapy Combined with Chemotherapy on Advanced Lung Cancer Patients: A Randomized, Double-blinded, Controlled Clinical Trial.

Conclusions: MF therapy could improve life quality and modulate blood cytokine concentration in advanced lung cancer patients. Hence, it might be applied as an adjuvant therapy along with chemotherapy. PMID: 32238091 [PubMed - as supplied by publisher]
Source: International Journal of Radiation Biology - Category: Radiology Tags: Int J Radiat Biol Source Type: research

Related Links:

Small-cell lung cancer (SCLC) accounts for approximately 12% of lung cancers [1]. Although SCLC is highly sensitive to first-line treatment, about 80% of limited-disease patients and almost all patients with extended disease show disease relapse or progression due to the emergence of drug-resistant tumor cells [2 –5]. Japan is presently aging at a rapid pace, and approximately 50% of all patients with SCLC in Japan are aged>70 years [6]. Advanced age is associated with an increased risk of lung cancer, and the increase in global life expectancy has resulted in a corresponding increase in the incidence of lung cancer.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
iki Karachaliou Rafael Rosell Treatment of advanced (metastatic) non-small-cell lung cancer (NSCLC) is currently mainly based on immunotherapy with antibodies against PD-1 or PD-L1, alone, or in combination with chemotherapy. In locally advanced NSCLC and in early resected stages, immunotherapy is also employed. Tumor PD-L1 expression by immunohistochemistry is considered the standard practice. Response rate is low, with median progression free survival very short in the vast majority of studies reported. Herein, numerous biological facets of NSCLC are described involving driver genetic lesions, mutations ad fusions,...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
This study aims to analyze the prognostic value of seven tumor makers and also investigate the response of palliative chemotherapy in advanced NSCLC patients with advanced disease.Methods: Medical records of 278 advanced NSCLC Chinese patients who received six cycles of palliative chemotherapy were retrospectively reviewed under ethical approval (JSCH2019K-011). Univariate and multivariate Cox regression analyses were performed using SPSS 24 to find the clinical value of these tumor markers and to identify the factors that were associated with progression-free survival (PFS), as well as the response to palliative chemother...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: The elcss-ql is feasible as a tool for use in routine clinical practice, although no statistically significant effect of its use was demonstrated in our study. Improving access to supportive care through the collection of patient-reported outcomes and hrqol should be an important component of care for patients with advanced lung cancer. PMID: 32489264 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Conclusions: This Canadian expert consensus statement and algorithm were driven by significant advances in the treatment of EGFR-mutated nsclc. PMID: 32489263 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Authors: Gordon N, Felix K, Daw NC Abstract Inhalation therapy remains a suitable approach to treat lung diseases including cancer. This approach has been used to deliver various therapies including chemotherapy. The rationale for using the inhalation route vs. the systemic route has been the fewer side effects encountered when drugs are administered via inhalation. Furthermore, this approach overcomes one of the major limitations of systemic chemotherapy that results from inability of the drug to reach high concentrations in the lungs. Local delivery overcomes this limitation and spares exposure of vital organs to...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Overall survival (OS) benefit derived from frontline treatment with nivolumab plus ipilimumab combined with 2 cycles of platinum-doublet chemotherapy in patients with metastatic or recurrent non-small cell lung cancer was further improved after at least 12 months of follow-up.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Frontline treatment with nivolumab plus ipilimumab induced durable and long-term efficacy, compared with chemotherapy, in patients with advanced non-small cell lung cancer, regardless of PD-L1 expression.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
ConclusionRegardless of the NSCLC patients who were less or more than 65  years, immune checkpoint inhibitors could achieve better OS than chemotherapy. But there was no significant difference when NSCLC patients who were more than 75 years old. Older patient should be offered immune therapies if it is possible and the mechanism in old age treatment should be further s tudied.
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: While pembrolizumab is superior to standard chemotherapy in improving overall survival and progression-free survival, results suggest that it is unlikely to be cost-effective at its current price in Singapore. Factors including clinical effectiveness, safety and budget impact should also be considered when making national funding decisions. PMID: 32462958 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Lung Cancer | Radiology | Study